Brief: Alcon Acquires Neurotech And Encelto, The Only FDA-Approved Treatment For Mactel Type 2
Tue 23:01
BRIEF-Alcon Acquires Neurotech And Encelto, The Only FDA-Approved Treatment For Mactel Type 2 Oct 20 (Reuters) - Alcon AG ALCC.S:
ALCON ACQUIRES NEUROTECH AND ENCELTO, THE ONLY FDA-APPROVED TREATMENT FOR MACTEL TYPE 2
ALCON AG - PAYS $550 MILLION TO BUY NEUROTECH PHARMACEUTICALS
ALCON AG - MAY MAKE ADDITIONAL CONTINGENT PAYMENTS FOR COMMERCIAL MILESTONES
ALCON AG: EXPECTS TRANSACTION TO BE MODESTLY ACCRETIVE TO NET SALES GROWTH AND SLIGHTLY DILUTIVE TO CORE DILUTED EPS IN 2027
ALCON AG: EXPECTS TRANSACTION TO BE ACCRETIVE AFTER 2027
Source text: ID:nBw9JjnLba
Further company coverage: ALCC.S
((((Reuters.Briefs@thomsonreuters.com;));))
Recent news on Alcon AG
See all newsBrief: Alcon Acquires Neurotech And Encelto, The Only FDA-Approved Treatment For Mactel Type 2
Brief: Alcon Acquires Neurotech And Encelto, The Only FDA-Approved Treatment For Mactel Type 2
Swiss stocks - Factors to watch on October 19
Brief: FDA Approves Alcon’S BRYTL Eye Drops
Advisory: Alert incorrectly tagged to Omega Interactive Technologies withdrawn